<DOC>
	<DOCNO>NCT02710630</DOCNO>
	<brief_summary>The primary objective trial investigate relative bioavailability five different tablet formulation Dabigatran Etexilate , Formulation A1 , Formulation B1 , Formulation C1 , Formulation D1 , Formulation E1 , compare commercial capsule formulation Dabigatran Etexilate . The secondary objective evaluate compare several pharmacokinetic parameter treatment .</brief_summary>
	<brief_title>Bioavailability Study Five Tablet Formulations Dabigatran Etexilate Compared Commercial Capsule Formulation Healthy Male Subjects</brief_title>
	<detailed_description />
	<mesh_term>Dabigatran</mesh_term>
	<criteria>Inclusion criterion : Healthy male subject accord investigator 's assessment , base complete medical history include physical examination , vital sign ( blood pressure [ BP ] , pulse rate [ PR ] ) , 12lead electrocardiogram ( ECG ) , clinical laboratory test Age &gt; =20 &lt; =35 year old Body mass index ( BMI ) &gt; =18.0 &lt; =25.0 kg/m2 Signed date write informed consent prior admission study accordance Good Clinical Practice ( GCP ) local legislation Exclusion criterion : Any find medical examination ( include BP , Pulse Rate , ECG ) deviate normal judge clinically relevant investigator screen Measurement systolic blood pressure outside range 90 140 mmHg , diastolic blood pressure outside range 50 90 mmHg , pulse rate outside range 45 90 bpm screen Any laboratory value outside reference range investigator considers clinical relevance Any relevant bleeding history consider investigator Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder Surgery gastrointestinal tract could interfere kinetics trial medication ( except appendectomy simple hernia repair ) Diseases central nervous system ( include limit kind seizure stroke ) , relevant neurological psychiatric disorder Any history evidence blood dyscrasia , haemorrhagic diathesis , severe thrombocytopenia , cerebrovascular haemorrhage , bleed tendency associate active ulceration overt bleed gastrointestinal , respiratory genitourinary tract disease condition haemorrhagic tendency History relevant orthostatic hypotension , faint spell , blackout Chronic relevant acute infection History relevant allergy hypersensitivity ( include allergy trial medication excipients ) Any evidence concomitant disease consider clinically relevant investigator Intake drug long halflife ( 24 hour ) within 30 day less 10 halflives respective drug prior administration trial medication Within 10 day prior administration trial medication , use drug might reasonably influence result trial Intake medication , influence blood clotting , e.g. , acetylsalicylic acid , coumarin etc . within 10 day prior trial medication Participation another trial investigational drug administer within 4 month 5 halflives ( whichever great ) prior plan administration trial medication Planned surgery within four week follow endof study examination Smoker ( 10 cigarette 3 cigar 3 pipe per day ) Inability refrain smoke inhouse confinement trial site Alcohol abuse ( consumption 30 g per day : e.g. , 750 mL beer , 1.5 gous [ equivalent 270 mL ] Sake ) Drug abuse positive drug screen Blood donation 100 mL within 30 day prior administration trial medication intend donation trial Intention perform excessive physical activity within one week prior administration trial medication trial Inability comply dietary regimen trial site Subject assess unsuitable inclusion investigator , instance , consider able understand comply study requirement , condition would allow safe participation study</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>